New Antibody Adds to Arsenal Against Dengue

July 10, 2015 Updated: July 10, 2015

Scientists have found a key piece of the puzzle needed to potentially cure or treat dengue. The virus infects about 400 million people worldwide annually and no licensed vaccine is currently available.

The research shows how an antibody neutralizes dengue virus serotype 2 (DENV-2). Published online in Science, the discovery could help with the development of dengue therapeutics.

Dengue virus has four serotypes (DENV1-4) circulating in nature, which makes it difficult to treat. To have complete protection against the dengue infection, a vaccine has to simultaneously stimulate an equally strong antibody response against all four serotypes. This, so far, has been proven difficult, as vaccines provide differing levels of protection against the serotypes. Latest clinical trials show good protection against DENV-3 and DEN-4, but poor protection against DENV-1 and no protection at all against DENV-2.

The team, led by Duke-NUS Graduate Medical School Singapore researchers Shee-Mei Lok and Gunter Fibriansah, demonstrated how a potent human derived antibody (2D22) can kill DENV-2.

In past research, Lok has shown that the DENV-2 is more complex than the rest of the dengue serotypes as the mosquito-derived virus has a highly dynamic structure which changes its form, or morphology, as it infects humans. This makes DENV-2 harder to kill.

While previously identified antibodies could only kill DENV-2 of a certain morphology, the newly discovered antibody can kill DENV-2 of all morphologies.

“This clearly illustrates the potential of using this antibody for dengue treatment,” she adds.

Lok’s overall strategy is to develop a safe therapeutic by combining four antibodies that inhibit infection of each of the dengue virus serotypes. Her team is now working on identifying an antibody effective against DENV-4 to complete the full set of antibodies and to use it to make an effective cocktail against all serotypes.

This research was a collaboration among researchers from Duke-NUS, Vanderbilt University, the University of North Carolina, and the University of California, Berkeley. and was supported by the Singapore Ministry of Education Academic Research Fund Tier 3.

This article was previously published by Duke-NUS.  Republished via Futurity.org under Creative Commons License 4.0.